Durham, NC (September 8, 2023) – Parion Sciences Inc. today announced publication in The Lancet Respiratory Medicine of positive results of the Phase 2 study of idrevloride in hypertonic saline in people with primary ciliary dyskinesia (PCD). In the CLEAN-PCD study, idrevloride in hypertonic saline was safe and associated with significant improvement in lung function over 28 days in people with primary ciliary dyskinesia compared with hypertonic saline alone.
Durham, NC, April 5, 2023 Parion Sciences (Parion) today announced receipt of a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) for the Paediatric Investigation Plan (PIP) for Idrevloride Inhalation Solution, an epithelial sodium channel (ENaC) inhibitor, currently in development for the treatment of primary ciliary dyskinesia (PCD).
Company Release November 17, 2020
Durham, NC. Parion Sciences, Inc. (Parion), a clinical-stage pharmaceutical company focused on treatments of unmet respiratory diseases, announced today, that on November 16, 2020, the European Commission has adopted the designation of P-1037 Inhalation Solution (P-1037 IS), a novel, epithelial sodium channel (ENaC) inhibitor, under evaluation as a potential treatment of primary ciliary dyskinesia (PCD), as an Orphan Drug. PCD is a serious disease that affects approximately 1 in 15,000 people worldwide.
Company Release July 29, 2020
Durham, NC. Parion Sciences, Inc. (“Parion”), a clinical-stage pharmaceutical company focused on treatments of unmet respiratory diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation to P-1037 Inhalation Solution (P-1037 IS). P-1037 IS, a novel, epithelial sodium channel (ENaC) inhibitor in a nebulized solution is being evaluated for the potential treatment of Primary Ciliary Dyskinesia (“PCD”).
Durham, NC (January 23, 2020) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary diseases, announced today that it has reached an agreement with Vertex Pharmaceuticals, Inc. to reacquire the pulmonary rights to epithelial sodium channel (ENaC) inhibitors developed under a collaboration announced between the parties in 2015. Under this agreement, Vertex is eligible to receive future undisclosed royalties based upon commercial success.
First-in-human trial encouraging, identifies agent that is associated with signs of improvement in tear function
Clinical Data to be presented for a novel device for transnasal delivery of a pulmonary aerosol in children with Cystic Fibrosis
Durham, NC (October 25, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its pulmonary research and development efforts will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida, October 27 through 29, 2016.
First Patient Enrolled in P-321-202 Clinical Trial
Durham, NC (July 26, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has initiated a phase 2 clinical trial of P-321 Ophthalmic Solution in patients with Dry Eye Disease (DED). P-321 is a potent inhibitor of the epithelial sodium channels (ENaC) on the ocular surface, and is expected to restore the tear film on the ocular surface in those patients with dry eye disease. Earlier this year the results of a Phase 1/2a safety, tolerability, and pharmacokinetics study in subjects with dry eye were presented.
Data on P-321 from clinical research to be presented on May 3rd
Durham, NC (May 2, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and epithelial diseases, announced today the presentation of a poster containing clinical data for the development stage dry eye treatment P-321. The presentation is a review of the results from a clinical trial of P-321 versus placebo in patients with dry eye disease and will be presented at the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington on May 3rd, 2016.
LIBOURNE FRANCE and DURHAM NC (January 19, 2016) — Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial sodium channel (ENaC) inhibitor to treat veterinary ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS) commonly called dry eye. Under the agreement, Ceva gains worldwide development and commercial rights to ZP-1 (P-1046). ZP-1 has successfully completed a proof-of-concept clinical trial in canine KCS. ZP-1 (P-1046) was originally discovered by Parion Sciences, Inc. and licensed to Zoion Pharma for veterinary use.